Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Pfizer on Monday said that its Covid-19 vaccines work for children aged 5 to 11 and will begin the procedure to seek US authorisation soon.
The vacccine is already available for anyone aged 12 and above. With kids back in school amidst an outbreak of delta variant, many parents are anxiously awaiting vaccinations for their younger children.
For testing purposes, Pfizer used a much lower dose - a third of the amount being administered currently. 'After receiving their second dose, the children developed coronavirus-fighting antibody levels just as strong as teenagers and young adults,' said Dr. Bill Gruber, a Pfizer senior vice president.
'I think we really hit the sweet spot,' continued Gruber, who's also a pediatrician.
Earlier, FDA chief Dr. Peter Marks told AP that once Pfizer turns over its study results, his agency would evaluate the data &ldquo;hopefully in a matter of weeks&rdquo; to determine if the shots are safe and effective.
'Once the vaccine is authorized for younger children, they'll be carefully monitored for rare risks just like everyone else.' said Pfizer's Gruber.

Pfizer vaccines effective in kids aged 5 to 11

'Ray of hope!': Ongoing study suggests Pfizer vaccine is effective in kids aged 5 to 11 amid delta variant outbreak in the U.S.

U.S.&nbsp;pharma&nbsp;giant Pfizer on Monday said that its Covid-19 vaccines work for children aged 5 to 11 and will begin the procedure to seek authorisation of the Joe Biden&nbsp;administration&nbsp;soon.
The Covid-19&nbsp;vaccine is already available for anyone aged 12 and above. With kids back in school amidst an outbreak of delta variant in the U.S., many parents are anxiously awaiting vaccinations for their younger children.
For testing purposes, Pfizer used a much lower dose - a third of the amount being administered currently. Pfizer senior vice president, Dr. Bill Gruber, said that after receiving their second dose, the children developed coronavirus-fighting antibody levels just as strong as teenagers and young adults.&nbsp;
Earlier, Food and Drug Administration chief Dr. Peter Marks told AP that once Pfizer turns over its study results, his agency would evaluate the data &ldquo;hopefully in a matter of weeks&rdquo; to determine if the shots are safe and effective.

Pfizer on Monday said that its vaccines work for children aged 5 to 11.&nbsp;The news comes as a ray of hope amid ongoing delta variant outbreak.
&nbsp;

U.S pharma&nbsp;giant Pfizer on Monday said that its Covid-19 vaccines work for children aged 5 to 11 and will begin the procedure to seek authorisation of the Joe Biden&nbsp;administration&nbsp;soon.
The Covid-19&nbsp;vaccine is already available for anyone aged 12 and above. With kids back in school amidst an outbreak of delta variant in the U.S., many parents are anxiously awaiting vaccinations for their younger children.
For testing purposes, Pfizer used a much lower dose - a third of the amount being administered currently. 'After receiving their second dose, the children developed coronavirus-fighting antibody levels just as strong as teenagers and young adults,' said Dr. Bill Gruber, a Pfizer senior vice president.
'I think we really hit the sweet spot,' continued Gruber, who's also a pediatrician.
Earlier, FDA chief Dr. Peter Marks told AP that once Pfizer turns over its study results, his agency would evaluate the data &ldquo;hopefully in a matter of weeks&rdquo; to determine if the shots are safe and effective.
'Once the vaccine is authorized for younger children, they'll be carefully monitored for rare risks just like everyone else.' said Pfizer's Gruber.

pfizer biontech

Categories